Targeting liver X receptors in XXXX health: deadlock or promising trail?

@entity1 @entity6 @entity5 @entity272 @entity19411 @entity74 @entity195 @entity731 @entity165
INTRODUCTION: Liver X receptors (LXR) are transcription factors that belong to the nuclear receptor superfamily. Natural derivatives of @entity165 , known as @entity19411 , have been identified as agonistic ligands of LXR. They are thus mainly considered to be intracellular @entity165 'sensors' whose activation leads to decreased plasma @entity165 . Their implication in other physiologic processes currently prevents their use as therapeutic targets, because of potentially deleterious side effects. AREAS COVERED: The various LXR agonists and antagonists, along with the physiological functions of LXR. Putative clinical targets including @entity731 , @entity6 , @entity195 , @entity272 , @entity74 and @entity5 . EXPERT OPINION: LXR are promising pharmacological targets because of the high potential to develop ligands owing to the variety of natural or synthetic agonists. Three aspects should be developed to select a LXR-ligand for treatment of @entity1 disease: bio-availability; isoform specificity; tissue specificity. This will allow the development of selective liver X modulators (SLiMs). The challenge is to overcome deleterious side effects to establish LXR as new pharmacological targets.
